Immune thrombocytopenia in dogs: low platelets and bleeding

Overview

Platelets, or thrombocytes, form in the bone marrow. They help blood clot. ITP is the most common acquired disorder of primary haemostasis in dogs, meaning the initial stage of stopping bleeding. Diagnosis excludes other causes of reduced platelets.

Very low counts may involve severe bleeding, but some dogs appear healthy despite a similar deficiency. Urgency therefore considers both clinical condition and blood results. Mortality as high as 27% has been reported in dogs with ITP. This reflects disease seriousness, but an individual's situation depends particularly on bleeding severity.

Causes

The immune system targets its own cells

Normally, platelets stick together and seal damaged vessels to stop blood loss.

An immune reaction against platelets speeds their removal from circulation. Less commonly, the target is marrow megakaryocytes, the cells producing platelets. In primary ITP, no triggering disease or other factor is identified. Secondary ITP involves an identified underlying factor.

Infections and other underlying factors

Possible associations include infections, medicines, tumours and inflammatory diseases. Strong evidence shows Ehrlichia canis infection can cause canine ITP. Other mechanisms besides immune destruction also contribute to low platelets in this infection.

Platelets may also fall through excessive consumption, poor production or accumulation in the spleen. Distinguishing these from ITP affects treatment choice. An inherited large-platelet condition, for example, must not be confused with antibody-mediated destruction.

Risk factors

Middle-aged females are overrepresented among ITP patients. Dogs with primary ITP are usually around 6–7 years old. However, ages range from 7 months to 14 years, so youth or old age does not exclude it.

Cocker Spaniels have a recognised predisposition. Predisposed breeds also include Poodles, Old English Sheepdogs and German Shepherd Dogs. Assessment reviews countries visited and exposure to fleas, ticks or other vectors. History also includes previous vaccinations, current and recent medicines and possible toxic exposures.

Typical symptoms

You may see bleeding at several sites: skin, gums, the eye, urine or gastrointestinal contents.

• Small red haemorrhages, called petechiae, appear on gums or skin.
• Larger-than-usual bruises develop.
• The nose bleeds.
• Urine contains blood.
• Stools contain blood or become black, called melaena.
• Vomit contains blood.
• Your dog is subdued, weak or unusually breathless.

Visible bleeding can also occur inside the eye. Conversely, even severe platelet deficiency may be found before visible signs. No signs therefore does not make a clearly abnormal result unimportant.

Complications and consequences

Blood loss and severe disease

Heavy bleeding can cause anaemia requiring transfusion. Bleeding into the brain or lungs indicates severe ITP. Black, bloody stools also accompany severe disease.

Circulatorily stable dogs with primary ITP have a good outlook when there is no anaemia or active bleeding. Bleeding location affects severity, so visible bruise numbers do not reflect every consequence of internal haemorrhage.

Recurrence

Reported ITP recurrence rates range from 9–47%. In one study, recurrence was typically early, at a median of 79 days. Possible causes include stopping immunosuppression too quickly, a new triggering disease or an initially hidden factor.

Diagnosis at the vet

The true platelet count is confirmed

A low automated count is checked on a blood smear, a thin blood layer examined microscopically. Platelets activated during collection or handling can produce a falsely low result. The count is repeated when needed. Using the same measurement method is preferred during monitoring.

A count below 30,000 platelets per microlitre was associated with spontaneous bleeding in a study. However, this does not directly establish whether an individual dog is bleeding, because clinical condition varies at similar counts.

The cause and consequences are investigated

Your vet reviews vaccinations, medicines, travel and parasite prevention. Examination includes skin, lymph nodes and the back of the eyes. A blood count is supplemented with biochemistry and urinalysis. Suspected ITP warrants combined antibody and PCR testing for Ehrlichia, Babesia and Anaplasma infections. Imaging looks for a tumour, inflammation or infection focus according to individual suspicion.

Bone marrow sampling is not routine for every dog with ITP. It is considered for unexplained reductions in other blood cell lines, for example. Demonstrating platelet antibodies alone does not confirm ITP either. Routine measurement is not recommended.

In Cavalier King Charles Spaniels, benign inherited macrothrombocytopenia, a large-platelet condition, must be distinguished. It occurs in around 30–50% of the breed. The asymptomatic inherited condition needs no treatment. Genetic testing can help avoid unnecessary, potentially harmful medication.

PT and aPTT clotting tests form part of basic investigation of low platelets. They help distinguish disseminated clotting disorders or anticoagulant rodenticide effects from primary ITP, for example. Markers of clot breakdown, such as D-dimer, may also be considered.

Treatment

Suppressing the immune reaction

Your vet prescribes ITP medication, with glucocorticoids a central medicine group. A second immunosuppressant may be added for inadequate response, serious adverse effects or relapse, for example. No particular combination has proved unequivocally best for every dog. Secondary ITP also requires treatment of the triggering disease.

Vincristine can be used as an additional treatment for clinically significant bleeding. Intravenous immunoglobulin is an alternative, for example if vincristine is unsuitable or ineffective. Poorly responsive cases may prompt consideration of splenectomy or treatment stimulating platelet production.

Bleeding support and recovery

Anaemia or blood loss-related circulatory insufficiency may require a red-cell-containing transfusion. Platelet-containing products are considered for severe or life-threatening bleeding, but are not routinely given to every ITP patient. Red blood cells and plasma separated from canine donations are used for seriously ill patients.

After glucocorticoids begin, most dogs' platelet counts rise to 50,000–100,000 per microlitre within 7 days. In one comparison, counts reached at least 50,000 per microlitre after a median of 4 days with combination treatment and 5 days with glucocorticoids alone. Groups were small, with 6 and 14 dogs. Complete response is defined as at least 100,000 platelets per microlitre without bleeding. Response during medication differs from remission maintained without medication.

In hospital, daily examination is performed and the blood count initially checked at least every 2–3 days. Active bleeding, anaemia or deterioration needs closer monitoring.

Gastroprotective medication is considered with confirmed or suspected melaena. Evidence is insufficient for its effect on outcomes in every dog with ITP. Antithrombotic medication is generally not part of treatment, but may be considered separately when bleeding risk is low and another disease predisposes to clots.

Unnecessary procedures are avoided and essential sampling performed gently by experienced staff. Sampling highly vascular organs is considered only if essential. Discharge decisions consider haematocrit stability, red cell transfusion need and platelet progress as well as bleeding.

Later outpatient blood checks may initially be every 1–2 weeks once active bleeding has stopped and platelets increased. During immunosuppression, biochemistry is considered at least monthly to monitor possible liver and kidney effects.

The ABCB1, or MDR1, mutation affects vincristine suitability, requiring particular caution in susceptible dogs because of adverse effect risk. Neutrophils, a white cell group, are monitored for possible reduction in dogs receiving vincristine.

Probiotics are not routinely recommended for ITP based on current evidence.

Prevention

The trigger for primary ITP is unknown, so no single preventive measure addresses an identified cause. Vaccination has been proposed as an association, but canine evidence for causation is limited. Vaccination after previous ITP is planned individually according to infection risk and protection needs. Antibody testing for some diseases can help assess protection.

Because of recurrence risk, medication changes follow your vet's plan only. Platelets are checked before planned medication reduction. Response monitoring relies on examination and blood counts. Repeated platelet antibody measurement is not recommended for response monitoring.

Important for dog owners

Keep a recovering dog rested and handling calm to avoid additional tissue injury. Soft food and avoiding hard chew toys reduce gum injury. A harness may form part of gentle handling.

Record new haemorrhages, black stools, bloody urine and condition changes to identify relapse. Follow-up also monitors treatment harms, including infections, digestive signs, liver injury and marrow suppression. In drug-free remission, monthly examination and blood counts are initially recommended for 3 months, then intervals can gradually increase.

If a dog with previous ITP is vaccinated, platelet checks at 2 and 5 weeks afterwards are considered.

Frequently asked questions

Does a low platelet count always mean immune disease?

Platelets can also decrease through consumption, production disorders or splenic accumulation. Sample-related interference can additionally produce a falsely low automated result. Low counts are therefore checked on a smear and interpreted alongside other investigations before diagnosing ITP.

Can an apparently well dog have very few platelets?

Some dogs seem clinically healthy despite extremely low counts. Another dog with similar counts may have life-threatening bleeding. Looking well therefore does not replace investigation or agreed laboratory checks.

Is ITP permanently cured by the first treatment?

ITP can recur after response, with reported relapse rates of 9–47%. Complete response during treatment differs from remission maintained without medication. Continuing monitoring therefore remains justified after bleeding stops and your dog looks healthy.

Does every dog need a bone marrow sample?

Bone marrow sampling is not recommended routinely for primary ITP. It may be needed if reductions in other blood cells remain unexplained. Diagnosis relies on an overall assessment rather than one special test, confirming true thrombocytopenia and systematically seeking alternatives.

Can a recovering dog chew bones or hard toys?

During active ITP, soft food and avoidance of hard chew toys are recommended to prevent gum injuries. Exercise is also restricted and handling kept gentle. Returning to normal activities is tailored to bleeding and your vet's assessment.